Last updated: July 1, 2026
Answer a few questions to find clinical trials matched to your specific Sarcoma situation.
Usually 2–3 minutes. No sign-up.
Find matching trials →Standard of care (subtype-specific): Localized soft tissue/bone — surgery ± radiation. Metastatic STS 1L — doxorubicin-based chemotherapy (typically doxorubicin ± ifosfamide; trabectedin and pazopanib in later lines). Osteosarcoma — MAP (methotrexate, doxorubicin, cisplatin) ± mifamurtide post-resection. Ewing sarcoma — VDC/IE alternating regimen. Advanced chondrosarcoma — largely chemotherapy-resistant; IDH1 inhibition is the first targeted approach. Desmoid — nirogacestat or sorafenib (active surveillance for stable disease). Epithelioid sarcoma — tazemetostat. Synovial sarcoma post-chemo — afami-cel (Tecelra) if HLA-A*02 + MAGE-A4+. ASPS — cabozantinib or atezolizumab. GIST: see our dedicated GIST page.
Before or alongside surgery for localized or resectable disease:
For previously untreated advanced/metastatic sarcoma (and newly diagnosed osteosarcoma):
After progression on first-line therapy:
Histology and/or biomarker entry requirements. These trials require specific subtype confirmation or molecular testing before screening:
Engineered T-cell therapies targeting intracellular tumor antigens via TCR (distinct from CAR-T, which targets cell-surface antigens). Requires HLA typing and tumor-antigen expression testing on biopsy:
Distinct from autologous TCR-T cell therapies (above), TCR-based bispecifics are off-the-shelf fusion proteins pairing an engineered soluble TCR (recognizing an intracellular tumor antigen on Class I HLA) with an anti-CD3 scFv that recruits polyclonal T cells. Also requires HLA typing on a blood draw:
Gastrointestinal stromal tumor is technically a sarcoma but has its own treatment ecosystem (KIT/PDGFRA TKIs) and a separate disease page. A few currently-recruiting Phase 3 examples for context:
Includes leiomyosarcoma, liposarcoma (dedifferentiated, well-differentiated, myxoid/round cell), synovial sarcoma, undifferentiated pleomorphic sarcoma, angiosarcoma, and others. Many of the trials listed above (NCT06422806 IO + chemo in DDLPS/UPS, NCT04031677 perioperative chemo in retroperitoneal LMS/DDLPS, NCT06389799 pemigatinib + retifanlimab in DDLPS, NCT07359053 MAGNATE-S, NCT07516925 ivonescimab in LMS) target specific STS subtypes. View all on ClinicalTrials.gov →
Dedifferentiated and well-differentiated liposarcomas are MDM2-amplified, making them a long-standing target for MDM2-p53 inhibitors. NCT06422806 (Phase 3 IO + chemo vs chemo in DDLPS/UPS) and NCT06389799 (pemigatinib + retifanlimab in DDLPS) are listed above. Myxoid/round cell liposarcoma has high NY-ESO-1 expression in some patients, potentially overlapping with TCR-T trials.
Doxorubicin-based 1L; trabectedin, pazopanib, and gemcitabine/docetaxel in later lines. Olaratumab approval was withdrawn after the ANNOUNCE-2 trial failed to confirm a survival benefit. Currently recruiting: NCT07516925 (ivonescimab PD-1/VEGF bispecific in LMS) and NCT04031677 (perioperative chemo in retroperitoneal LMS/DDLPS, Phase 3). The APROMISS Phase 3 LMS cohort (NCT03016819) has closed enrollment per the corpus listing.
Translocation-driven (SS18-SSX). Uniquely amenable to TCR-T cell therapy when MAGE-A4 or NY-ESO-1 expression and matching HLA-A*02 type are confirmed on biopsy. Afamitresgene autoleucel (Tecelra) was FDA approved August 2, 2024 (adults). Mipetresgene autoleucel (NCT07174427) is in Phase 3 for NY-ESO-1+ disease. SPEARHEAD-3 (NCT05642455) extends afami-cel to pediatric patients. BRD9 inhibitors are an emerging research target for synovial sarcoma in earlier-phase trials.
Rare, indolent, translocation-driven (TFE3 fusion). Cabozantinib (Cabometyx) and atezolizumab have both shown activity. Currently recruiting: APROMISS (NCT03016819), a Phase 3 trial of anlotinib (catequentinib) in ASPS — the ASPS cohort remains open per the corpus listing. ClinTrialFinder will surface ASPS-specific arms within larger sarcoma baskets.
Higher checkpoint-inhibitor response rates than most other STS subtypes (single-agent pembrolizumab activity in SARC028 and follow-on studies). Currently recruiting in Phase 3: NCT06422806 (IO + chemo vs chemo alone in DDLPS/UPS, listed above).
Paclitaxel is the most common backbone; UV-induced angiosarcoma (head/neck cutaneous) has high tumor mutational burden and may respond to checkpoint inhibitors. Radiation-associated angiosarcoma (breast) and primary visceral angiosarcoma have distinct biology. Search active angiosarcoma trials → ClinicalTrials.gov. See also our melanoma trials page for related UV-driven solid tumors.
Often arises in patients with neurofibromatosis type 1 (NF1). Selumetinib is FDA approved for inoperable plexiform neurofibromas in pediatric NF1 (precursor lesions). MEK + MDM2 inhibitor combinations (selumetinib + APG-115, NCT06735820) are in early development for NF1-driven MPNST. SPEARHEAD-3 (NCT05642455 above) includes MPNST patients if MAGE-A4+ and HLA-A*02.
Locally invasive but does not metastasize — technically not a sarcoma but a connective-tissue tumor, included here because sarcoma centers manage them and trials often appear in sarcoma indexes. Nirogacestat (Ogsiveo, gamma-secretase inhibitor) was FDA approved November 2023 for progressing desmoid tumors. Recent ongoing trials include NCT07176689 (nirogacestat ovarian-function study in premenopausal women) and NCT05949099 (cryoablation + nirogacestat). Sorafenib remains an active alternative.
Characterized by loss of SMARCB1 (INI1). Tazemetostat (Tazverik, EZH2 inhibitor) is FDA approved for advanced epithelioid sarcoma. Currently recruiting: NCT07089992 (pembrolizumab in ultra-rare sarcomas including epithelioid) and NRSTS2021 (NCT06239272) for non-rhabdomyosarcoma soft tissue sarcomas.
Osteosarcoma is the most common primary bone cancer (adolescents/young adults; MAP regimen + surgery is standard; mifamurtide post-resection in some regimens; cabozantinib post-MAP in trials). NCT05691478 (cabozantinib added to chemo in newly diagnosed osteosarcoma, Phase 2/3) is listed above. Ewing sarcoma carries the EWSR1 translocation (pediatric/young adult; VDC/IE backbone). Chondrosarcoma is historically chemoresistant; IDH1 inhibition (ivosidenib, NCT06127407 above) is the first targeted approach for the IDH1/2-mutant subset. View all bone sarcoma trials →
Rhabdomyosarcoma is predominantly pediatric and is the most common pediatric soft tissue sarcoma. Pediatric Ewing sarcoma and osteosarcoma are covered by COG (Children's Oncology Group) cooperative-group trials and Phase 3 NCT06669013 (chemo-immunotherapy in patients under 18 with bone/STS). SPEARHEAD-3 (NCT05642455) covers pediatric synovial sarcoma, MPNST, neuroblastoma, and osteosarcoma. Families should also ask about pediatric-specific sarcoma centers and St. Jude / COG-affiliated institutions.
Covered on our dedicated GIST trials page — including PEAK (bezuclastinib + sunitinib), olverembatinib for SDH-deficient GIST, NB003, and the KIT/PDGFRA TKI landscape (imatinib, sunitinib, regorafenib, ripretinib, avapritinib).
Immunotherapy shows variable activity across sarcoma subtypes; combinations with chemotherapy or radiation are being explored to broaden responder populations. Notable: NCT06422806 Phase 3 IO + chemo in DDLPS/UPS, NCT06669013 Phase 3 pediatric chemo-immunotherapy, NCT07049848 SATURN-STS neoadjuvant atezolizumab. View all →
Doxorubicin, ifosfamide, gemcitabine/docetaxel, and other agents remain the backbone of treatment. View all →
MDM2 inhibitors (DDLPS/WDLPS), CDK4/6 inhibitors, FGFR inhibitors, IDH1/2 inhibitors (chondrosarcoma), tyrosine kinase inhibitors (ASPS, GIST), gamma-secretase inhibitors (desmoid), EZH2 inhibitors (epithelioid sarcoma), and NTRK fusion inhibitors (rare fusion-positive sarcomas).
Which sarcoma subtype do I have, and why does it matter for trial matching?
Sarcoma is an umbrella term covering 70+ subtypes across soft tissue (leiomyosarcoma, liposarcoma, synovial, UPS, angiosarcoma, MPNST, ASPS, epithelioid, desmoid), bone (osteosarcoma, Ewing, chondrosarcoma), GIST, and pediatric sarcomas (rhabdomyosarcoma). Many recruiting trials enroll only one subtype or require a specific biomarker (IDH1 for chondrosarcoma, MAGE-A4 or NY-ESO-1 for synovial, SDH for GIST, NF1 for MPNST). Your pathology report names the subtype — bring it to ClinTrialFinder when you search.
How do I find a sarcoma specialist or sarcoma center?
Sarcoma is rare (~1% of adult cancers) and outcomes are better at high-volume sarcoma centers. Look for an NCI-designated cancer center with a dedicated sarcoma program, or check the Sarcoma Alliance, Desmoid Tumor Research Foundation, or Ewing Sarcoma Research Trust for patient navigators. Many recruiting trials are only open at sarcoma-specialty sites — ClinTrialFinder will show you the participating locations for each match.
How do I find sarcoma clinical trials I'm eligible for?
Paste your medical summary into ClinTrialFinder to get AI-matched sarcoma trials in minutes. The tool considers your sarcoma subtype, tumor grade, biomarker status (IDH1, MAGE-A4, NY-ESO-1, SDH, NF1), prior treatments, and pediatric vs adult status across soft tissue, bone, GIST, and rare subtypes.
What sarcoma trials are currently recruiting?
There are 455 recruiting interventional sarcoma trials (July 2026) including 26 Phase 3 studies. Notable Phase 3 trials include ivosidenib for IDH1-mutated chondrosarcoma, olverembatinib for SDH-deficient GIST, anlotinib (APROMISS) for alveolar soft part sarcoma, mipetresgene autoleucel (NY-ESO-1 TCR-T) for synovial sarcoma, perioperative chemotherapy for high-risk retroperitoneal DDLPS/LMS, and immunotherapy plus chemotherapy in advanced DDLPS and UPS.
Are there cell therapy or TCR-T trials for synovial sarcoma?
Yes. Afamitresgene autoleucel (Tecelra, MAGE-A4 TCR-T) was FDA approved August 2, 2024 for advanced synovial sarcoma in HLA-A*02 + MAGE-A4-positive adults who have received prior anthracycline or ifosfamide — it was the first TCR-T therapy approved for any solid tumor. Mipetresgene autoleucel (TBI-1301) is in Phase 3 for NY-ESO-1 positive synovial sarcoma (NCT07174427). SPEARHEAD-3 (NCT05642455) extends afami-cel to pediatric MAGE-A4+ patients. Eligibility requires both a matching HLA type and the corresponding tumor antigen confirmed on biopsy. TCR-T differs from CAR-T in that it targets intracellular antigens via T-cell receptors, whereas CAR-T targets cell-surface antigens.
Find Sarcoma Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific sarcoma subtype and treatment history.
Find Matching Trials